Researchers have discovered a new approach to overcome chemotherapy resistance in clear cell ovarian cancer by using low doses of 2-deoxy-D-glucose. The treatment has shown significant improvement in laboratory models and is expected to be safer for patients with reduced side effects.
The TAILORx trial found that women on hormone therapy also experienced cognitive decline, which leveled off over time. Cognitive function did not return to pre-treatment levels in either group, and hormone therapy may play a role in this impairment.
A study published in Neuro-Oncology Advances suggests that chemotherapy can be effective against diffuse intrinsic pontine glioma (DIPG), a devastating childhood brain cancer. Researchers found that the medicine reaches DIPG tissue in good quantities, offering new hope for treatment.
Combining therapeutic HPV vaccine ISA101 with chemotherapy drugs carboplatin and paclitaxel may extend survival in patients with advanced cervical cancer. The vaccine was well-tolerated, reducing suppressive myeloid cells to better stimulate T cell responses.
A new trial has found that chemotherapy after surgery significantly reduces the risk of rare kidney cancer returning. The treatment has been shown to increase survival rates by over half, with 71% of patients living cancer-free for three years or more.
The study found that patients whose breast cancer was completely eradicated by chemotherapy had a higher proportion of DNA mutational 'signature 3', indicating defects in DNA repair. This signature is associated with genes like BRCA, which could help doctors predict patient response to neoadjuvant chemotherapy.
A team of NUS researchers identified a novel protein S1P2 that can protect nerve cells from damage and pain when activated with a drug-like compound. This discovery holds promise for the prevention and treatment of chemotherapy-induced neuropathy, as well as other forms of neuropathy.
Researchers developed a novel method to analyze chemotherapy-resistant tumors using circulating tumor cells. Single-cell RNA sequencing revealed gene expression differences between individual cells, providing insight into the evolution of multiple resistance mechanisms.
A University of Colorado Cancer Center study found that patients with locally advanced rectal cancer who received lower-than-recommended doses of neoadjuvant chemotherapy experienced a complete response and tumor shrinkage similar to those receiving the full dose.
A pilot study conducted by INRS researchers highlights the effect of chemotherapy on male fertility before and after puberty. The study found that all patients were at higher risk of infertility due to low sperm production, regardless of age at diagnosis.
Scientists identified a new biological pathway (RICTOR/mTORC2) as a potential therapeutic target for colon cancer. Targeting this pathway could enhance the effectiveness of chemotherapy treatments. The study also highlights the importance of SMAD4 gene mutations in colon cancer progression.
A new clinical trial has shown that giving men one cycle of chemotherapy is as effective at preventing testicular cancer from coming back as two cycles. This reduction in chemotherapy dosage lowered debilitating side effects, improving patients' quality of life.
A recent study found that obesity is a significant risk factor for cardiotoxicity in breast cancer patients treated with chemotherapy, particularly those receiving anthracyclines and trastuzumab. The study suggests that overweight and obese individuals may benefit from careful cardiac screening and follow-up during treatment.
A new study led by Christine B. Ambrosone found that breast cancer patients taking antioxidants during chemotherapy had a 41% increased risk of disease recurrence and a similar but weaker risk of death. Patients using vitamin B12, iron, and omega-3 fatty acid supplements also showed poorer outcomes.
A Mayo Clinic study of 5,540 patients with metastatic colorectal cancer found that maintenance chemotherapy after initial treatment is more beneficial for patients whose disease is under control. The preferred regimen is fluoropyrimidine with or without bevacizumab, according to the analysis.
A study published in SPIE Journal of Biomedical Optics found that diffuse reflectance spectroscopy can reliably discriminate between healthy tissue and tumor tissue, regardless of neoadjuvant chemotherapy status. The technique's feasibility for tumor-margin assessment during breast-conserving surgery has been demonstrated.
Researchers have developed 'combo' nanoplatforms using graphene oxide and reduced graphene oxide to enhance chemotherapy therapy. These nanocarriers can target tumors and improve drug delivery, reducing side effects on normal cells/tissues.
Researchers at the University of Texas MD Anderson Cancer Center found that secondary tumor-reduction surgery followed by chemotherapy did not result in longer survival than chemotherapy alone. The study involved 240 patients with platinum-sensitive recurrent ovarian cancer and showed that complete tumor resection was associated with i...
Researchers created a test using tumor organoids to predict how patients with advanced colorectal cancer respond to chemotherapy treatment. The test correctly classified 80% of patients treated with irinotecan, suggesting it could help identify those who won't benefit from toxic chemotherapies.
A new analysis published in Annals of Oncology suggests that hormone therapy has a greater impact on women's quality of life compared to chemotherapy, especially in postmenopausal patients. This finding challenges current international guidelines recommending prolonged hormone therapy for 5-10 years.
A University of South Florida researcher is studying whether a home-based exercise program can decrease the severity of nerve and muscle symptoms from chemotherapy-induced peripheral neuropathy in breast cancer survivors. The study aims to provide an evidence-based intervention for patients suffering from persistent neuropathy.
A recent study presented at the ESMO Congress 2019 found that nearly four times more patients responded to immunotherapy with pembrolizumab than standard chemotherapy in a trial for advanced mesothelioma. However, these responses did not delay progression or improve survival rates.
The TAILORx trial has shown that women with high Recurrence Scores (26-100) have a 93% chance of being cancer-free after five years, with those receiving chemotherapy having a significantly better outcome. The findings support the use of adjuvant chemotherapy to improve treatment outcomes in early breast cancer patients.
The CheckMate-227 trial found that the combination of nivolumab and low-dose ipilimumab improves overall survival in patients with advanced non-small cell lung cancer compared to chemotherapy. The treatment was well-tolerated, with a low rate of discontinuation and treatment-related toxicities.
Researchers at Medical College of Georgia have found a link between high levels of TIMP-1 and IL-6, two molecules that contribute to chemotherapy resistance in non-small cell lung cancer. The study's findings suggest that elevated levels of these molecules may be an indicator of poor prognosis and a potential target for improving treat...
Researchers at Mayo Clinic discovered that inhibiting GSK-3 enzyme sensitizes pancreatic cancer cells to gemcitabine, a commonly used chemotherapy. This new approach may overcome resistance to chemotherapy and improve treatment outcomes for patients with pancreatic cancer.
Researchers discovered that some cancer cells survive chemotherapy by consuming neighboring tumor cells, providing energy to stay alive. This process helps senescent cancer cells initiate tumor relapse after treatment completion.
A new clinical trial, EAZ171, is recruiting black women with breast cancer to investigate and treat taxane-induced neuropathy. The study seeks to identify the most effective chemotherapy regimen for African American women, who are disproportionately affected by this debilitating side effect.
The KEYNOTE-024 trial found that pembrolizumab significantly improved progression-free and overall survival in patients with advanced non-small-cell lung cancer. Patients treated with pembrolizumab had a median overall survival of 26.3 months compared to 14.2 months for those on chemotherapy.
The Impower131 Trial found that atezolizumab + chemotherapy improved overall survival by 3.9 months compared to chemotherapy alone, particularly among patients with high PD-L1 expression. Treatment-related side effects were common but manageable in both arms.
Researchers studied the relationship between tumor mutational burden and response to immunotherapy with pembrolizumab. The study found that high or low TMB levels did not significantly impact overall survival, progression-free survival, or objective response rates for patients with metastatic nonsquamous non-small cell lung cancer.
Researchers found no significant correlation between tumor mutational burden and response rates, progression-free survival, or overall survival in patients treated with pembrolizumab plus carboplatin and pemetrexed. High objective response rates were observed in both TMB low and high subgroups.
A recent study found that certain molecules in chemotherapy drugs react differently to radiation when in water compared to gas. This affects the ionization process and can improve the way radiation is used for cancer treatment.
A new study published in Annals of Surgical Oncology suggests that delaying chemotherapy after breast cancer surgery can lead to poorer overall survival. The research found that patients who received postoperative chemotherapy within four months of diagnosis had better survival rates than those whose treatment was delayed.
Researchers at the University of Nottingham have discovered that delivering chemotherapy drugs via a biodegradable paste during brain cancer surgery can lead to long-term survival. The treatment, using a combination of etoposide and temozolomide, was found to be effective in rat models with glioblastoma multiforme (GBM) tumors.
Researchers discovered that a repurposed heart drug can overcome chemotherapy resistance in over a third of ependymoma patients. The study found that the presence of ABCB1, a protein pumping out chemotherapy drugs, is associated with poorer outcomes and lower survival rates.
A new diagnostic test has the potential to determine if breast cancer patients require chemotherapy, giving them control over their treatment. The test uses gene profiling to identify low-risk patients who may not benefit from chemotherapy.
The NRG-GOG 0258 trial showed that carboplatin and paclitaxel chemotherapy alone resulted in comparable recurrence-free survival rates compared to combined modality treatment. The study found a reduced incidence of vaginal, pelvic, and para-aortic lymph node recurrences but increased distant recurrences with combined modality treatment.
A study led by Northwestern University found that radiation combined with chemotherapy did not increase recurrence-free survival in women with stage III/IVA endometrial cancer. Chemotherapy alone remains the standard of care for this type of cancer.
SMU researchers develop a new approach to treat drug-resistant prostate cancer cells using a protein inhibitor and chemotherapy. The method shows promising results, increasing sensitivity of cancer cells to chemotherapeutics without harming healthy cells.
A Phase II clinical trial conducted at MD Anderson Cancer Center revealed an 84.6% overall response rate and 38.5% complete response rate when combination targeted therapy was given prior to chemotherapy for newly diagnosed patients with a specific type of diffuse large B-cell lymphoma. The findings suggest that patients who respond to...
A new clinical trial shows that immunotherapy pembrolizumab is more effective than standard aggressive chemotherapy in treating people with recurrent head and neck cancer. The combination of pembrolizumab with platinum chemotherapy extended survival by 3.7 months, while the immunotherapy alone showed improved survival rates compared to...
The study's primary endpoint showed that the total neoadjuvant therapy (TNT) approach was safe, associated with high rates of chemotherapy completion (>90%), but did not demonstrate a significant improvement in reducing cancer presence at surgery. Veliparib addition resulted in more side effects and reduced chemoradiation completion, y...
A Cancer Research UK-funded study found that less chemotherapy is as effective at controlling disease for elderly or frail patients with advanced stomach or oesophagus cancer. The study showed that lower doses of chemotherapy resulted in fewer side effects and improved quality of life.
A global study predicts a 53% rise in chemotherapy demand by 2040, with an estimated 15 million patients needing treatment annually. The study recommends expanding the chemotherapy workforce to 100,000 physicians by 2040 to deliver optimal treatment.
A new multigene test called EndoPredict has been found to predict chemotherapy benefit in women with hormone receptor-positive, HER2-negative breast cancer. The test was successful in identifying patients who would benefit from chemotherapy and those who could opt out of the treatment.
A new study suggests that genetic testing, such as Oncotype DX, can help women with early-stage hormone-positive breast cancer avoid chemotherapy and save on treatment costs. The test is estimated to cost around $3,400, and its use could lead to a 8% reduction in chemotherapy costs, resulting in savings of about $338 million annually.
Triple negative breast cancer cells can temporarily turn on molecular pathways protecting them from chemotherapy, making them vulnerable to targeted therapy IACS-10759. This discovery offers a new treatment option for resistant TNBC patients.
A Mayo Clinic study found that extended chemotherapy, a normal CA 19-9 tumor marker, and a dead tumor after surgery can significantly increase survival time for patients with advanced pancreatic cancer. The study achieved an average survival time of 58.8 months, or nearly five years.
Researchers found that tumor-associated macrophages release compounds that block the action of gemcitabine in malignant cells. The study suggests that patients with fewer macrophages in their tumors may respond better to chemotherapy. This discovery could lead to new approaches for treatment.
The NRG Oncology trial suggests adding docetaxel-based chemotherapy to standard treatment should be considered for men with high-risk prostate cancer. The study found improved overall survival, disease-free survival, and reduced rates of distant metastases.
Despite the risks, many health care workers do not use recommended personal protective equipment when handling chemotherapy. A study from Michigan Medicine found that nurses who reported handling hazardous drugs had twice the risk of reproductive problems.
A study published in Annals of Oncology found that one course of chemotherapy or radiotherapy after surgery does not have a long-term effect on sperm count and concentration in men with early stage testicular cancer. Sperm number and concentration recovered in all groups up to five years after treatment.
University of Alberta researchers have discovered a way to make chemotherapy more effective against cancer while blocking its harmful side effects on the heart. By stabilizing a specific metabolic protein, they were able to prevent heart damage and enhance tumor regression in preclinical mouse models.
Scientists at the University of Missouri developed a patient-specific vaccine to treat osteosarcoma in dogs, avoiding chemotherapy and improving survival rates. The treatment has shown promising results, with dogs receiving immunotherapy experiencing over 400 days of remission compared to 270 days for those receiving chemotherapy.
Researchers have developed a 'drug sponge' that can absorb up to 64% of chemotherapy drugs from the bloodstream, potentially reducing toxic side effects. The technology uses an absorbent polymer coating on a 3D-printed cylinder inserted into a vein, which sops up excess drugs before they reach other organs.
Scientists have created a 3D-printed device that can absorb excess chemotherapy drugs from a patient's bloodstream before they spread to healthy cells. The device captured about 64% of doxorubicin, a commonly used chemotherapy drug, reducing the likelihood of side effects such as hair loss and nausea.
Researchers found that chemotherapy can induce tumors to release exosomes containing a protein that stimulates immune cells to attract cancerous cells, leading to metastasis. Neutralizing this protein or blocking immune cells may improve the efficacy and safety of neoadjuvant chemotherapy.
The MYSTIC trial found that first line immunotherapy combination with durvalumab and tremelimumab does not improve overall survival in unselected patients with lung cancer. However, a subgroup of patients with high tumour mutational burden showed improved overall survival with the combination treatment.
A phase III trial found that using circulating tumor cell count to guide treatment choice can lead to a significant gain in overall survival. Patients with estrogen receptor-positive, HER2-negative metastatic breast cancer who received chemotherapy based on high CTC counts had better progression-free and overall survival rates.